Navigation Links
New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
Date:12/10/2008

ves of women with advanced breast cancer.

"Researching new cancer treatments is a complex step by step process. Each success helps lay the foundation for the next step forward," said William M. Burns, CEO Division Roche Pharmaceuticals. "These results show that we are making significant progress towards giving doctors and their breast cancer

patients better and more effective treatment options to fight this devastating disease at all stages," he added.

    Presentation of Data

    Herceptin

    Gianni L et al  Neoadjuvant trastuzumab in patients with   Friday 12th,
                    HER2-positive locally advanced breast      December
                    cancer: primary efficacy analysis of the   09:30 hrs
                    NOAH trial                                 General
                                                               Session 3
                                                               (Hall D)

    Xeloda

    Joensuu H et    Significant improvement in                 Sunday 14th,
    al. for The     recurrence-free survival (RFS)             December
    Finnish Breast  when capecitabine (X) is                   11:45 hrs
    Cancer Group    integrated into docetaxel (T)              General
                    5-FU + epirubicin + cyclophosphamide       Session 7
                    (CEF) adjuvant therapy for high-risk
                    early breast cancer (BC): interim
                    analysis of the FinXX-trial.

    Avastin

    Smith IE et al  Primary analysis of study MO19391, an      Saturday
                    open-label safety study of bevacizumab     13th,
                    plus taxane-based therapy as 1st-line      December
                    treatment of patients with locally         07:00 hrs
                    recurrent or metastatic breast cancer.     Poster
                                                               Session 4

'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
5. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
6. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
7. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
11. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... PHILADELPHIA , July 7, 2015 ... and complex civil litigation law firm with one ... in the U.S, joined co-counsel Faruqi and Faruqi, ... lawsuits against pharmaceutical manufacturers AstraZeneca Pharmaceuticals LP, Cephalon, ... $55.5 million, plus statutory fees.  Under the agreements, ...
(Date:7/7/2015)... June 30, 2015 ... announced the addition of the "Biomedical ... their offering. This patent landscape ... imaging is a safe, non-invasive, non-ionizing imaging ... represents a great alternative to traditional medical ...
(Date:7/7/2015)... , July 7, 2015 A power morcellator ... has been settled for an undisclosed amount, Bernstein Liebhard ... filed in March 2014 in the U.S. District Court, ... behalf of a widower whose wife had died in ... a hysterectomy that involved the use of a power ...
Breaking Medicine Technology:AstraZeneca, Cephalon, and Biogen Idec to Pay $55.5 Million to Resolve False Claims Act Allegations Made By Whistleblower Ronald Streck 2AstraZeneca, Cephalon, and Biogen Idec to Pay $55.5 Million to Resolve False Claims Act Allegations Made By Whistleblower Ronald Streck 3Worldwide Biomedical Photoacoustic Imaging Patent Landscape Report 2015 2Worldwide Biomedical Photoacoustic Imaging Patent Landscape Report 2015 3Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 2Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 3
(Date:7/7/2015)... Washington (PRWEB) , ... July ... ... San Francisco-based Hope Consulting announced today that the two firms have merged ... in the social, health and biopharma sectors. The merger combines SwitchPoint’s strategy ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... The United ... AIDS Action Committee of Massachusetts , and the Multicultural AIDS Coalition $3.78 ... other men who have sex with men (MSM) and transgender women, the groups ...
(Date:7/7/2015)... New York, NY (PRWEB) , ... July 07, 2015 , ... ... , the email newsletter and website that helps active people find the most fun ... health and active lifestyle coverage for millennials. It also increases Greatist’s opportunity for events, ...
(Date:7/7/2015)... ... July 07, 2015 , ... Celestix ... CelestixEdge VE and CelestixFederated VA Series virtual appliances. These virtual platforms expand ... of products, which have proven to simplify the on-premises deployment of unified remote ...
(Date:7/7/2015)... ... , ... Quadrino Law Group is pleased to announce the relocation of the ... The new facility is a state of the art building, located with easy access ... CEO and founder, said, "We are pleased to service our clients from such a ...
Breaking Medicine News(10 mins):Health News:SwitchPoint and Hope Consulting Have Merged to Form Camber Collective 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 3Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 2Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 3Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 4
... 8, 2009) Carole Wagner Vallianos, Esq., president and ... Medical Center (LA BioMed), will be inaugurated as the president ... Chicago on July 30. Founded in 1913, the American ... lawyers and other members of the public who seek to ...
... REGISTER NOW , , CHICAGO, July 9 ... streets of Chicago, the American Cancer Society Charity Runner Team ... Marathon. , , , "The Society is thrilled ... Chicago Marathon," said Alison Tibbits, project manager, fundraising resources, American ...
... ... power to the Washington Nationals to raise awareness of diabetes and support the creation of a ... , ... -- Nick Jonas of the Jonas Brothers has lent his star power to the Washington Nationals ...
... physicians can improve the health of high-risk patients by ... treatment plan recommendations with primary care physicians, according to ... British Medical Journal. , , The ... can take a more active role in managing the ...
... Hereditary angioedema (HAE) is an autosomal dominant disease ... causes recurrent attacks of intense localized edema involving the ... attenuated androgens or plasmin inhibitors has been the mainstay ... acute treatment are on the horizon. It is important ...
... who had first period before age 12 are at increased risk ... Among women with ovarian cancer, those who had their first menstrual ... menstrual cycles over a lifetime are more likely to die of ... study shows. , U.S. researchers analyzed data on 410 women, aged ...
Cached Medicine News:Health News:LA BioMed President and CEO will be named president of the American Judicature Society 2Health News:Calling All Runners: Join the Fight Against Cancer 2Health News:Nick Jonas Joins with Washington Nationals to Support Children with Diatbetes 2Health News:Kaiser Permanente Project Proves Electronic Health Information and Care Coordination Improve Chronic Disease Management 2Health News:Kaiser Permanente Project Proves Electronic Health Information and Care Coordination Improve Chronic Disease Management 3Health News:Kaiser Permanente Project Proves Electronic Health Information and Care Coordination Improve Chronic Disease Management 4Health News:Changing Paradigms in Hereditary Angioedema: A Focus on Timely Diagnosis and New Therapies 2Health News:Early Menstruation Lowers Odds of Surviving Ovarian Cancer 2Health News:Early Menstruation Lowers Odds of Surviving Ovarian Cancer 3
The ACP 215 is the automated closed system cell processor with integrated process control....
... Enhanced Durability for Excellent ... working with challenging cases. PT² ... of a linear elastic nitinol ... resilient polymer tip. This provides ...
... PCS2 system is Haemonetics ... collection of plasma and ... the collection of "jumbo" ... platelet-poor plasma with optional ...
The COBE 2991 Cell Processor provides reliable, automated cell processing, with the control you need to get reproducible results in your lab. This versatile machine offers users reliability and multi...
Medicine Products: